openPR Logo
Press release

Metabolic Syndrome Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Torrent Pharma Ltd., AstraZeneca, Sanofi, Eli Lilly and Company, GlaxoSmithKline, Pfizer, Novartis, Kos Pharmaceutical, Merck Sharp

07-17-2023 04:58 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Metabolic Syndrome Market to Observe Impressive Growth During

DelveInsight's "Metabolic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Metabolic Syndrome, historical and forecasted epidemiology as well as the Metabolic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metabolic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metabolic Syndrome Market Forecast
https://www.delveinsight.com/sample-request/metabolic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Metabolic Syndrome Market Report:
• The Metabolic Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The American Heart Association (AHA), [2021] reports that the prevalence of metabolic syndrome in the United States has increased to 34%
• The American Heart Association estimates that almost three million people in the United States, or more than 9% of children and adolescents aged 12 to 19, have the metabolic syndrome
• Key Metabolic Syndrome Companies: Torrent Pharma Ltd., AstraZeneca, Sanofi, Eli Lilly and Company, GlaxoSmithKline, Pfizer, Novartis, Kos Pharmaceutical, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Daiichi Sankyo, Novo Nordisk, Johnson & Johnson, Dainippon Sumitomo Pharma, and others
• Key Metabolic Syndrome Therapies: TRC150094, Rosuvastatin, clopidogrel, LY518674, GW677954, Atorvastatin, Fluvastatin, Pioglitazone, Simvastatin, Micardis, Olmesartan medoxomil, and others
• The Metabolic Syndrome epidemiology based on age-specific cases analyzed that metabolic syndrome is common in the older people and prevalence increases with aging
• The Metabolic Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metabolic Syndrome pipeline products will significantly revolutionize the Metabolic Syndrome market dynamics.

Metabolic Syndrome Overview
The American Heart Association (AHA) defines metabolic syndrome as the existence of a collection of risk factors that are particular to cardiovascular disease. The chance of acquiring diabetes, heart disease, stroke, or all three is significantly increased by metabolic syndrome. Age-related increases in the prevalence of MetS impact more than 40% of persons in their 60s and 70s.

Get a Free sample for the Metabolic Syndrome Market Report
https://www.delveinsight.com/report-store/metabolic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metabolic Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metabolic Syndrome Epidemiology Segmentation:
The Metabolic Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Metabolic Syndrome
• Prevalent Cases of Metabolic Syndrome by severity
• Gender-specific Prevalence of Metabolic Syndrome
• Diagnosed Cases of Episodic and Chronic Metabolic Syndrome

Download the report to understand which factors are driving Metabolic Syndrome epidemiology trends @ Metabolic Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/metabolic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metabolic Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metabolic Syndrome market or expected to get launched during the study period. The analysis covers Metabolic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metabolic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metabolic Syndrome Therapies and Key Companies
• TRC150094: Torrent Pharmaceuticals Limited
• Rosuvastatin: AstraZeneca
• clopidogrel: Sanofi
• LY518674: Eli Lilly and Company
• GW677954: GlaxoSmithKline
• Atorvastatin: Pfizer
• Fluvastatin: Novartis
• Pioglitazone: Kos Pharmaceutical
• Simvastatin: Merck Sharp & Dohme LLC
• Micardis: Boehringer Ingelheim
• Olmesartan medoxomil: Daiichi Sankyo

Discover more about therapies set to grab major Metabolic Syndrome market share @ Metabolic Syndrome Treatment Market
https://www.delveinsight.com/sample-request/metabolic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metabolic Syndrome Market Strengths
• Metabolic Syndromeis a frequently used modality for cancer treatment. As a result, a huge population suffers from Metabolic Syndrome, which presents a huge market to any new entrant.
• The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease.

Metabolic Syndrome Market Unmet Needs
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Metabolic Syndrome Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Metabolic Syndrome Companies: Torrent Pharma Ltd., AstraZeneca, Sanofi, Eli Lilly and Company, GlaxoSmithKline, Pfizer, Novartis, Kos Pharmaceutical, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Daiichi Sankyo, Novo Nordisk, Johnson & Johnson, Dainippon Sumitomo Pharma, and others
• Key Metabolic Syndrome Therapies: TRC150094, Rosuvastatin, clopidogrel, LY518674, GW677954, Atorvastatin, Fluvastatin, Pioglitazone, Simvastatin, Micardis, Olmesartan medoxomil, and others
• Metabolic Syndrome Therapeutic Assessment: Metabolic Syndrome current marketed and Metabolic Syndrome emerging therapies
• Metabolic Syndrome Market Dynamics: Metabolic Syndrome market drivers and Metabolic Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metabolic Syndrome Unmet Needs, KOL's views, Analyst's views, Metabolic Syndrome Market Access and Reimbursement

To know more about Metabolic Syndrome companies working in the treatment market, visit @ Metabolic Syndrome Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/metabolic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Metabolic Syndrome Market Report Introduction
2. Executive Summary for Metabolic Syndrome
3. SWOT analysis of Metabolic Syndrome
4. Metabolic Syndrome Patient Share (%) Overview at a Glance
5. Metabolic Syndrome Market Overview at a Glance
6. Metabolic Syndrome Disease Background and Overview
7. Metabolic Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Metabolic Syndrome
9. Metabolic Syndrome Current Treatment and Medical Practices
10. Metabolic Syndrome Unmet Needs
11. Metabolic Syndrome Emerging Therapies
12. Metabolic Syndrome Market Outlook
13. Country-Wise Metabolic Syndrome Market Analysis (2019-2032)
14. Metabolic Syndrome Market Access and Reimbursement of Therapies
15. Metabolic Syndrome Market Drivers
16. Metabolic Syndrome Market Barriers
17. Metabolic Syndrome Appendix
18. Metabolic Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Metabolic Syndrome Epidemiology https://www.delveinsight.com/report-store/metabolic-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metabolic Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Metabolic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metabolic Syndrome Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Torrent Pharma Ltd., AstraZeneca, Sanofi, Eli Lilly and Company, GlaxoSmithKline, Pfizer, Novartis, Kos Pharmaceutical, Merck Sharp here

News-ID: 3134087 • Views:

More Releases from DelveInsight Business Research

Vascular Dementia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP
Vascular Dementia Market Report 2032: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Vascular Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vascular Dementia, historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Vascular Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vascular Dementia Market Forecast https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Ph
Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA App …
Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market. The Limb Girdle Muscular Dystrophy
RIPK1 Inhibitor Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharm
RIPK1 Inhibitor Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approv …
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "RIPK1 Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market. The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the
Atypical Teratoid Rhabdoid Tumors Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuti
Atypical Teratoid Rhabdoid Tumors Pipeline Report, 2024 Updates : In-depth Analy …
Atypical Teratoid Rhabdoid Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Atypical Teratoid Rhabdoid Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Atypical Teratoid Rhabdoid Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atypical Teratoid Rhabdoid Tumors Market. The Atypical Teratoid Rhabdoid Tumors

All 5 Releases


More Releases for Metabolic

Comprehensive Metabolic Panel Testing Market Size
The findings reviewed by GME stated that the Global Comprehensive Metabolic Panel Testing Market will grow from USD 11.5 billion in 2021, to USD 13.8 billion in 2026 with a CAGR value of 7.5%. Factors like the rising prevalence of chronic diseases, increasing prevalence of Covid-19 and increasing patients, technological advancements, increasing disposable income, growing geriatric population, emphasis on early diagnosis and treatment are expected to support the growth of
Therapeutic Proteins for Metabolic Disorders Treatment Market is Driven by Incre …
Therapeutic Proteins for Metabolic Disorders Treatment Market: Introduction Therapeutic proteins are proteins which are engineered in a laboratory for pharmaceutical use. Therapeutic proteins are used as a personalized treatment approach which supports a precisely targeted therapeutic process by making up for the deficiency of an essential protein. Therapeutic proteins are deliberately adjusted to increase their clinical potential which is followed by enhancements derived from protein or glycol engineering, Fc fusion, or conjugation
Inherited Metabolic Disorders Market Comprehensive Survey 2025
Global Inherited Metabolic Disorders Market: Overview Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic
Metabolic Testing Market Opportunity Analysis, 2018-2026
Metabolic testing involves assessment of health and wellbeing of an individual. Metabolic testing equipment are used to screen organ functions and disease condition such as liver diseases, diabetes, kidney diseases, and cardiovascular diseases. Metabolic syndrome is a group of metabolic disorders such as high blood pressure with high fasting glucose levels and abnormal obesity. Metabolism pattern and metabolic capacity is determined with the help of metabolic testing for management of
Inherited Metabolic Disorders Market Felicitous over 2025
Global Inherited Metabolic Disorders (IMD) Market: Snapshot Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations. Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate
Inherited Metabolic Disorders Market Current Trends by 2025
Global Inherited Metabolic Disorders (IMD) Market: Snapshot Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations. Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate